Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01545570 · ClinicalTrials.gov registry record · Phase 1

A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers

A Phase 1 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 1
Development phase
82
Enrollment target

NCT01545570 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 82 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01545570, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 1
Development phase
82 participants
Enrollment target

Study Summary

This is a single-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2374697 in healthy volunteers. The study will enrol approximately 72 subjects at one clinical study center in the United States.

Interventions

  • DRUG 0.9% sodium chloride
  • DRUG GSK2376497

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 2011-11-07
Est. Completion 2012-12-23
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT01545570

The ClinicalTrials.gov registry entry for NCT01545570 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which 0.9% sodium chloride is the first listed.

NCT01545570 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01545570 about?

NCT01545570 is a clinical study titled "A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers". This is a single-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2374697 in healthy volunteers. The study will enrol approximately 72 subjects at one clinical study center in the U...

What is the current status of trial NCT01545570?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2011-11-07. Estimated completion is 2012-12-23.

What interventions are being tested in trial NCT01545570?

The interventions under investigation include: 0.9% sodium chloride (DRUG), GSK2376497 (DRUG).

Who is sponsoring clinical trial NCT01545570?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.